Insulin is often labelled a “fat-storage hormone,” particularly when it comes to harmful belly fat. Yet GLP-1 therapies — drugs that enhance insulin release — consistently reduce visceral fat and lower the risk of heart attack and stroke. How can this be?

This article explains the apparent paradox in clear, patient-friendly language. It explores how insulin normally works, why constant insulin exposure — driven by frequent carbohydrate intake — promotes visceral fat over time, and how GLP-1 drugs restore healthier insulin timing rather than increasing insulin burden. It also explains the role of slowed gastric emptying, smoother glucose absorption, and reduced portal insulin exposure, helping dangerous belly fat shrink gradually.

Drawing on major clinical trials and imaging studies, the article also considers why reducing visceral fat matters for long-term heart health — and why this biology may be relevant to cancer risk as well.

plus-circle Add Review

comment

Reviews